Christopher Fundakowski
Thomas Jefferson University, Thomas Jefferson University Hospital
Papers
2
Total Citations
51
H-Index
2
About
Christopher Fundakowski is a leading head and neck surgical oncologist whose research focuses on the intersection of immunotherapy, smoking-related outcomes, and minimally invasive surgery in head and neck cancers. His most-cited work investigates how smoking adversely affects survival in patients with HPV-positive oropharyngeal cancer treated with transoral robotic surgery, a finding that has shaped risk stratification for this growing patient population. In a landmark 2020 study (38 citations), Fundakowski demonstrated that smokers with HPV-positive disease face worse prognosis even with advanced surgical techniques, challenging assumptions about favorable outcomes in this group. More recently, his 2023 study (13 citations) broke new ground by examining complication rates following neoadjuvant immune checkpoint inhibition before surgery for head and neck squamous cell carcinoma—a critical safety analysis as immunotherapy moves into preoperative settings. Fundakowski’s work bridges surgical innovation and immunotherapy, providing evidence-based guidance for treatment sequencing and patient selection. His contributions are essential reading for clinicians and researchers navigating the evolving landscape of head and neck cancer care, where smoking history and immune checkpoint inhibitors increasingly dictate therapeutic decisions.
Research Focus
Key Achievements
Top Papers
- 1
- 2